Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century.

Abstract:

:The epidemiology of meningococcal disease in Europe since 1945 has shown fluctuations in incidence, serogroup distribution and case-fatality rate. Outbreaks and epidemics driven by the introduction of new virulent strains into Europe have occurred unpredictably. Epidemics associated with serogroups A and B have occurred in all regions of the continent. Additionally, there have been periods of increased outbreak frequency, such as those associated with serogroup C in the 1980s and 1990s, against an endemic disease incidence of around one to two cases per 100,000 population. Serogroup W135 disease was observed in the 1970s and again in 2000, while serogroup Y has recently emerged in Sweden and the Czech Republic. This article describes the changing epidemiology of meningococcal disease in Europe. An understanding of this is important for informed decision-making about different meningococcal vaccines that may be considered for use in Europe.

journal_name

Expert Rev Vaccines

authors

Kriz P,Wieffer H,Holl K,Rosenlund M,Budhia S,Vyse A

doi

10.1586/erv.11.117

subject

Has Abstract

pub_date

2011-10-01 00:00:00

pages

1477-86

issue

10

eissn

1476-0584

issn

1744-8395

journal_volume

10

pub_type

历史文章,杂志文章,评审
  • Insect cell technology is a versatile and robust vaccine manufacturing platform.

    abstract::Baculovirus and insect cell culture technologies have mostly been limited to research laboratories for the transient expression of target proteins for drug development purposes. With the renaissance of the vaccine field and the regulatory acceptance of recombinant DNA technology, the baculovirus expression system has ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.24

    authors: Mena JA,Kamen AA

    更新日期:2011-07-01 00:00:00

  • Vaccination and healthy aging.

    abstract::The aging process in humans is associated with a decrease in immune function (immunosenescence) and an increase in comorbid disorders. When combined with environmental factors this can lead to an increased risk and severity of infectious diseases. Diseases in older adults (>/=70 years) tend to be more severe and have ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.26

    authors: Maggi S

    更新日期:2010-03-01 00:00:00

  • Immunological mechanisms of specific immunotherapy with pollen vaccines: implications for diagnostics and the development of improved vaccination strategies.

    abstract::This review deals with specific immunotherapy performed with pollen vaccines. Pollen allergens, the immunological mechanism of allergic inflammation and the mechanisms behind successful specific immunotherapy treatment of seasonal pollen allergy shall be discussed. The different approaches to develop improved regimes ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.1.85

    authors: Movérare R

    更新日期:2003-02-01 00:00:00

  • Expanding access to non-traditional vaccines: a perspective from Indonesia.

    abstract::In addition to the use of traditional vaccines in the National Immunization Program, the introduction: of additional vaccines in Indonesia appears to be important to further reduce rates of childhood mortality. However, it typically takes at least two decades for additional vaccines to be introduced into the National ...

    journal_title:Expert review of vaccines

    pub_type: 社论

    doi:10.1586/14760584.2014.944165

    authors: Suwantika AA,Postma MJ

    更新日期:2014-12-01 00:00:00

  • Effect of HIV exposure and timing of antiretroviral therapy initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and hepatitis B vaccines.

    abstract:OBJECTIVES:We evaluated memory responses and antibody persistence to diphtheria-toxoid, tetanus-toxoid, whole-cell-pertussis (DTwP), and Hepatitis-B vaccines in HIV-unexposed, HIV-exposed-uninfected and HIV-infected children previously randomized to initiate time-limited ART at 6-10 weeks (ART-Immed) or when clinically...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14760584.2019.1547195

    authors: Simani OE,Izu A,Nunes MC,Violari A,Cotton MF,Van Niekerk N,Adrian PV,Madhi SA

    更新日期:2019-01-01 00:00:00

  • Vaccines against atherosclerosis.

    abstract::Atherosclerosis is the primary cause of acute myocardial infarction and stroke. It is well established that arterial inflammation in response to accumulation and oxidation of lipoproteins in the vascular wall is the major factor responsible for the development of atherosclerosis. During recent years, it has become app...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.13.4

    authors: Nilsson J,Wigren M,Shah PK

    更新日期:2013-03-01 00:00:00

  • An overview of in silico vaccine design against different pathogens and cancer.

    abstract:INTRODUCTION:Due to overcome the hardness of the vaccine design, computational vaccinology is emerging widely. Prediction of T cell and B cell epitopes, antigen processing analysis, antigenicity analysis, population coverage, conservancy analysis, allergenicity assessment, toxicity prediction, and protein-peptide docki...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1080/14760584.2020.1794832

    authors: Kardani K,Bolhassani A,Namvar A

    更新日期:2020-08-01 00:00:00

  • Systematic review of the clinical development of group B streptococcus serotype-specific capsular polysaccharide-based vaccines.

    abstract:INTRODUCTION:Vaccination against group B Streptococcus (GBS) during pregnancy could provide protection against disease in the mother, fetus, and newborn. Immunity through transplacental acquired antibodies in the newborns could persist through early infancy, reducing the risk of early-onset (<7 days age) and late-onset...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1080/14760584.2018.1496021

    authors: Dzanibe S,Madhi SA

    更新日期:2018-07-01 00:00:00

  • Current and emerging immunotherapeutic approaches to treat and prevent peanut allergy.

    abstract::Peanut-allergen hypersensitivity reactions, which can result in anaphylactic episodes and death, affect approximately 1% of the general population. Currently, strict avoidance of allergenic food is the only available treatment for this food-induced allergic reaction; however, the innocuous presence of trace amounts of...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.12.119

    authors: Miller DS,Brown MP,Howley PM,Hayball JD

    更新日期:2012-12-01 00:00:00

  • Typhoid vaccination: the Asian experience.

    abstract::The WHO has recently issued updated recommendations for the programmatic use of new-generation typhoid vaccines in high-risk areas of countries where typhoid fever is still endemic. Countries have subsequently been instructed to discuss how these recommendations can be implemented and to develop plans for targeted typ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.5.547

    authors: DeRoeck D,Ochiai RL,Yang J,Anh DD,Alag V,Clemens JD

    更新日期:2008-07-01 00:00:00

  • Fluzone® High-Dose Influenza Vaccine.

    abstract:INTRODUCTION:Fluzone® High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 µg hemagglutinin of each influenza strain, which is four times the hemagglutinin content of standard-dose influenza vaccines, including Fluzone (IIV3-...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1254044

    authors: Robertson CA,DiazGranados CA,Decker MD,Chit A,Mercer M,Greenberg DP

    更新日期:2016-12-01 00:00:00

  • An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.

    abstract::With the exception of alum, emulsion-based vaccine adjuvants have been administered to far more people than any other adjuvant, especially since the 2009 H1N1 influenza pandemic. The number of clinical safety and immunogenicity evaluations of vaccines containing emulsion adjuvants has correspondingly mushroomed. In th...

    journal_title:Expert review of vaccines

    pub_type: 历史文章,杂志文章,评审

    doi:10.1586/14760584.2013.811188

    authors: Fox CB,Haensler J

    更新日期:2013-07-01 00:00:00

  • Development of a Chlamydia trachomatis vaccine for urogenital infections: novel tools and new strategies point to bright future prospects.

    abstract:INTRODUCTION:The "cloaked" bacterial pathogen that is Chlamydia trachomatis continues to cause sexually transmitted infections (STIs) that adversely affect the health and well-being of children, adolescents and adults globally. The reproductive disease sequelae follow unresolved or untreated chronic or recurrent asympt...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1417044

    authors: Hafner LM,Timms P

    更新日期:2018-01-01 00:00:00

  • Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.

    abstract::Lipopolysaccharide (LPS), a dominant component of the Gram-negative bacterial outer membrane, is a strong activator of the innate immune system, and thereby an important determinant in the adaptive immune response following bacterial infection. This adjuvant activity can be harnessed following immunization with bacter...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1026808

    authors: Zariri A,van der Ley P

    更新日期:2015-06-01 00:00:00

  • The challenge of assessing infant vaccine responses in resource-poor settings.

    abstract::Newborns and infants are highly susceptible to infectious diseases, resulting in high mortality and morbidity, particularly in resource-poor settings. Many vaccines require several booster doses, resulting in an extensive vaccine schedule, and yet there is still inadequate protection from some of these diseases. This ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.41

    authors: Flanagan KL,Burl S,Lohman-Payne BL,Plebanski M

    更新日期:2010-06-01 00:00:00

  • 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.

    abstract::The global burden of disease due to Streptococcus pneumoniae remains high. The licensed 7-valent pneumococcal conjugate vaccine (7vCRM, Prevenar/Prevnar) has successfully reduced invasive disease in the USA, but serotype coverage is incomplete and some evidence suggests that serotype replacement has occurred. Recently...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.113

    authors: Prymula R,Schuerman L

    更新日期:2009-11-01 00:00:00

  • Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors.

    abstract::C-type lectin receptors (CLRs) are a class of pathogen-recognition receptors that are actively investigated in the field of vaccine delivery. Many of their properties have functions linked to the immune system. These receptors are expressed abundantly on antigen-presenting cells and are considered to be the sentinels ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.7.1005

    authors: Tang CK,Sheng KC,Apostolopoulos V,Pietersz GA

    更新日期:2008-09-01 00:00:00

  • Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.

    abstract::Serogroup B Neisseria meningitidis is the leading cause of meningococcal disease in developed countries. There is currently no vaccine offering wide-ranging protection. Development of a serogroup B polysaccharide-based vaccine has been hindered by potential risks of autoantibodies that cross-react with glycosylated ho...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.116

    authors: Bai X,Borrow R

    更新日期:2010-10-01 00:00:00

  • T-cell immunity generated by recombinant adenovirus vaccines.

    abstract::Recombinant adenovirus vaccines show great promise for generating protective immunity against infectious agents and tumors. Our studies have identified several interesting biological features of the adenovirus vector that influence the T-cell response. Notably, we have demonstrated that following immunization with ade...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.6.3.347

    authors: Yang TC,Millar JB,Grinshtein N,Bassett J,Finn J,Bramson JL

    更新日期:2007-06-01 00:00:00

  • Clinical peptide vaccination trials for leukemia patients.

    abstract::The favorable graft-versus-leukemia (GVL) effect that occurs after stem cell transplantation suggests that T cells can eradicate leukemia blasts. T cells specifically recognize peptides and exert an antileukemia effect. Several leukemia-associated antigens (LAAs) have been found to be overexpressed in malignant cells ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.56

    authors: Casalegno-Garduño R,Schmitt A,Schmitt M

    更新日期:2011-06-01 00:00:00

  • CpG DNA as a vaccine adjuvant.

    abstract::Synthetic oligodeoxynucleotides containing unmethylated CpG motifs act as immune adjuvants, accelerating and boosting antigen-specific antibody responses by up to 500-fold. CpG motifs promote the production of T-helper 1 and pro-inflammatory cytokines and induce the maturation/activation of professional antigen-presen...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.2.305

    authors: Klinman DM

    更新日期:2003-04-01 00:00:00

  • Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics.

    abstract:INTRODUCTION:Intranasal influenza vaccines are expected to confer protection among vaccine recipients by successful induction of mucosal immune response in the upper respiratory tract. Though only live attenuated influenza virus vaccines (LAIVs) are licensed and available for intranasal use in humans today, intranasal ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1507743

    authors: Sano K,Ainai A,Suzuki T,Hasegawa H

    更新日期:2018-08-01 00:00:00

  • Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.

    abstract::The need for an affordable, safe and effective HIV vaccine has never been greater. As the immunogenicity of all the vaccine vectors being evaluated currently in human populations is limited, novel vaccine strategies are needed to stimulate the innate immune system, to generate high levels of neutralizing antibodies an...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.5.6.827

    authors: Joseph J,Saubi N,Pezzat E,Gatell JM

    更新日期:2006-12-01 00:00:00

  • FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.

    abstract::The Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical and clinical (Phase I-III) vaccine trials against canine visceral leishmaniasis (92-95% of protection and 76-80% of vaccine efficacy) when formulated with a QS21 saponin-containing adjuvant. It became the licensed Leishmune...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.7.6.833

    authors: Palatnik-de-Sousa CB,Barbosa Ade F,Oliveira SM,Nico D,Bernardo RR,Santos WR,Rodrigues MM,Soares I,Borja-Cabrera GP

    更新日期:2008-08-01 00:00:00

  • Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy.

    abstract::Cancer immunotherapy has recently emerged as an important treatment modality. FDA approval of provenge, ipilimumab and pembrolizumab has started to deliver on the long awaited promise of cancer immunotherapy. Many new modalities of immunotherapies targeting cytotoxic T lymphocytes (CTLs) responses, such as adoptive ce...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.982101

    authors: Sharma RK,Chheda ZS,Jala VR,Haribabu B

    更新日期:2015-04-01 00:00:00

  • The value of HIV protective epitope research for informed vaccine design against diverse viral pathogens.

    abstract::The success of vaccine regimens against viral pathogens hinges on the elicitation of protective responses. Hypervariable pathogens such as HIV avoid neutralization by masking protective epitopes with more immunogenic decoys. The identification of protective, conserved epitopes is crucial for future vaccine candidate d...

    journal_title:Expert review of vaccines

    pub_type: 社论

    doi:10.1586/14760584.2014.928597

    authors: Kramer VG,Byrareddy SN

    更新日期:2014-08-01 00:00:00

  • Antigens of Corynebacterium pseudotuberculosis and prospects for vaccine development.

    abstract::Corynebacterium pseudotuberculosis continues to cause considerable economic losses in ovine and caprine herds worldwide, causing caseous lymphadenitis. Nevertheless, the immunology of this disease is relatively unknown. Novel antigens may provide vaccines that are more effective and improve diagnostic methods for bett...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.8.2.205

    authors: Dorella FA,Pacheco LG,Seyffert N,Portela RW,Meyer R,Miyoshi A,Azevedo V

    更新日期:2009-02-01 00:00:00

  • Host immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design.

    abstract::Infections of humans with Bacillus anthracis are an issue with respect to the biothreat both to civilians and military personnel, infections of individuals by infected livestock in endemic regions and, recently, infections of intravenous drug users injecting anthrax-contaminated heroin. Existing vaccination regimens a...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.981533

    authors: Altmann DM

    更新日期:2015-03-01 00:00:00

  • Perspectives on vaccination in adults.

    abstract::In the Second Conference on Controversies in Vaccination in Adults, leading vaccine experts among manufacturers, physicians, microbiologists, virologists, immunologists and public health specialists came together to discuss recent approaches, developments and strategies in vaccination against worldwide pressing epidem...

    journal_title:Expert review of vaccines

    pub_type:

    doi:10.1586/erv.13.44

    authors: Doerr HW

    更新日期:2013-06-01 00:00:00

  • Developmental immunology and vaccines: cellular immune development and future vaccine strategies.

    abstract::This section deals with how new knowledge of the development of cellular immunity in the neonatal period informs vaccine development and reviews the immune responses of the most vulnerable group of newborns, those born prematurely, to vaccines. It describes how the development of future vaccine strategies relies on a ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.3.4.339

    authors: Prescott S

    更新日期:2004-08-01 00:00:00